Announcements Trials
Browse Landscape

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 38Kidney Neoplasms 20Melanoma 14Neoplasm Metastasis 13Prostatic Neoplasms 6Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Uterine Cervical Neoplasms 4Colorectal Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Merkel Cell 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Lymphoma 2Carcinoma, Hepatocellular 2Anus Neoplasms 2Vaginal Neoplasms 1Turcot syndrome 1Skin Neoplasms 1Penile Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Multiple Myeloma 1Microsatellite Instability 1Mesothelioma, Malignant 1

Interventions

Docetaxel 4radium Ra 223 dichloride 2Prednisone 2sargramostim 1gossypol acetic acid 1epothilone B 1cabazitaxel 1bafetinib 1Sunitinib 1PE regimen 1Mycobacterium w vaccine 1Interleukin-2 1Injections 1Everolimus 1Etoposide 1Denosumab 1Cyclophosphamide 1Cisplatin 1Carboplatin 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hormone Refractory Prostate Cancer × Interleukin-2 × Genitourinary × Clear all
NCT02867345 2019-03-06

PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer

Peking University

Withdrawn
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡